Loading stock data…
NAMS
$28.43-0.13 (-0.46%)
Market ClosedLast close May 1
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NewAmsterdam Pharma Company N.V. in the Healthcare sector is trading at $28.43. The stock is currently 32% below its 52-week high of $42.00, remaining 10.3% below its 200-day moving average. Technical signals show oversold RSI of 19 and bearish MACD signal, explaining why NAMS maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 19) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$28.43
Potential Upside
5%
Whystock Fair Value$29.85
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Mean target$49.62+74.5%
Range$37.86 – $61.27
Fundamentals
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP)...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.67B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.13
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
5.18%
Volume
Today's trading volume
1.38M
Recent News
A Look At NewAmsterdam Pharma (NAMS) Valuation As Hedge Funds Focus On Obicetrapib’s Phase 3 LDL C Results
Hedge fund interest and Phase 3 data put NewAmsterdam Pharma in focus NewAmsterdam Pharma (NAMS) has drawn fresh attention after appearing among billionaire Stan Druckenmiller’s preferred small and mid cap names, with institutional interest centering on obicetrapib’s Phase 3 LDL C lowering results. See our latest analysis for NewAmsterdam Pharma. NewAmsterdam Pharma’s share price has moved to US$34.01, with a 10.53% 1 month share price return and a 3.66% 7 day gain. The 1 year total...
NewAmsterdam Pharma Company (NAMS): Huge Upside Potential Grabs Attention of Billionaire Stan Druckenmiller
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is one of Billionaire Stan Druckenmiller’s 10 Small and Mid-Cap Stock Picks with Huge Upside Potential. NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a relatively recent addition to the 13F portfolio of Duquesne Capital. The fund first disclosed a stake in the company in the third quarter of 2024. This position […]
Here’s Why NewAmsterdam Pharma Company N.V. (NAMS) Surged 23% in Q4
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The strategy returned 3.70% (gross) and 3.45% (net) in the fourth quarter compared to a 1.22% return for the Russell 2000 Growth Index. In 2025, the strategy […]
Upcoming Obicetrapib Phase 3 Data at ACC.26 Might Change The Case For Investing In NewAmsterdam Pharma (NAMS)
NewAmsterdam Pharma Company N.V. announced it will present multiple new data analyses on its oral CETP inhibitor obicetrapib for hypercholesterolemia at the American College of Cardiology Annual Scientific Session (ACC.26) in New Orleans on March 28–30, 2026, including results from the Phase 3 BROADWAY trial and pooled Phase 3 safety data. The planned presentations spotlight obicetrapib’s potential to pair LDL-lowering efficacy with a placebo-like safety profile and preserved kidney function...
This Biotech Was Quietly Bought Before a $58 Per Share Takeout
This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials.